贝伐珠单抗的疗效预测研究现状  

Progress in Response Prediction for Bevacizumab in Anti-tumor Therapy

作　　者：吴志勇[1] 吴倩[1] 孙德聪[2] 王治宽[1] 石燕[1] 戴广海[1] 

机构地区：[1]解放军总医院肿瘤综合治疗科,北京100853 [2]南开大学医学院临床医学系,天津300071

出　　处：《现代生物医学进展》2014年第23期4570-4573,4540,共5页Progress in Modern Biomedicine

基　　金：吴阶平基金项目(320.6750.12401);国家自然科学基金项目(81372286)

摘　　要：抗血管生成的贝伐珠单抗已被广泛应用于多种恶性肿瘤的治疗。但因其受益人群有限及逐渐出现的获得性耐药,也限制了其对患者总生存的改善。迫切需要寻找有效的预测贝伐珠单抗疗效的预测因子指导临床应用。人们在生物标记物、影像学方面进行了大量探索,但目前尚没有一个公认的普遍适用的临床预测指标,仍需要从多角度出发,进行进一步的基础研究及临床研究去发现和验证有效的疗效预测指标。Bevacizumab has been widely used in the treatment of a variety of neoplasms. However, some patients do not respond or gradually develop resistance, resulting in rather modest gains in terms of overall survival. It is urgent to find surrogate marker that can guide selection of patients for whom bevacizumab therapy is most beneficial. Although a large number of exploration has been done in biomarkers and imaging, there is no one recognized universally applicable clinical predictors yet. Thus more basic researches and clinical trials should be performed to find out effective surrogate markers in bevacizumab＇s therapy.

关 键 词：贝伐珠单抗 肿瘤 治疗 疗效预测 

分 类 号：R735.9[医药卫生—肿瘤]